ENDRA Life Sciences Inc. (NASDAQ:NDRA) Sees Significant Growth in Short Interest

ENDRA Life Sciences Inc. (NASDAQ:NDRA) saw a significant growth in short interest in February. As of February 13th, there was short interest totaling 58,719 shares, a growth of 27.0% from the January 29th total of 46,244 shares. Based on an average trading volume of 23,319 shares, the short-interest ratio is presently 2.5 days. Approximately 8.7% of the company’s shares are short sold. Approximately 8.7% of the company’s shares are short sold. Based on an average trading volume of 23,319 shares, the short-interest ratio is presently 2.5 days.

ENDRA Life Sciences Stock Down 5.5%

Shares of ENDRA Life Sciences stock traded down $0.21 on Wednesday, hitting $3.64. 53,286 shares of the company’s stock traded hands, compared to its average volume of 246,799. ENDRA Life Sciences has a 52-week low of $2.90 and a 52-week high of $11.96. The stock has a market cap of $2.73 million, a P/E ratio of -0.14 and a beta of -0.08. The firm’s 50-day moving average is $4.19 and its 200 day moving average is $4.95.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in ENDRA Life Sciences stock. Altium Capital Management LLC purchased a new stake in ENDRA Life Sciences Inc. (NASDAQ:NDRA) in the fourth quarter, according to its most recent filing with the SEC. The fund purchased 51,900 shares of the company’s stock, valued at approximately $235,000. ENDRA Life Sciences comprises 0.9% of Altium Capital Management LLC’s portfolio, making the stock its 17th biggest position. Altium Capital Management LLC owned approximately 6.92% of ENDRA Life Sciences as of its most recent filing with the SEC. 1.19% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently weighed in on NDRA. Weiss Ratings restated a “sell (e+)” rating on shares of ENDRA Life Sciences in a report on Wednesday, January 21st. Wall Street Zen raised ENDRA Life Sciences to a “sell” rating in a research report on Saturday, November 22nd. Finally, Ascendiant Capital Markets dropped their price objective on shares of ENDRA Life Sciences from $38.00 to $30.00 and set a “buy” rating on the stock in a research note on Monday, December 8th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $30.00.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.